Roth Capital Defends Questcor, Says Buy the Dip

Shares of Questcor Pharma

are down 6.5 percent Friday afternoon following reports on Thursday of an Aetna

review which showed H.P. Acthar was "medically necessary" only for infants with seizures. Roth Capital analyst Yale Jen called the sell off a chance to buy some stock. Jen noted the bulletin on Thursday was nearly "identical" to the prior policy update from September. The analyst believes the bulletin does not add "negativity" to Questcor fundamentals. Roth Capital maintains a Buy rating and $47 price target on shares of Questcor.